Wuhan Healthgen Biotechnology Corp. (SHA:688765)
39.84
+0.37 (0.94%)
Sep 30, 2026, 4:00 PM EDT
SHA:688765 Revenue
Wuhan Healthgen Biotechnology had revenue of 6.95M CNY in the quarter ending September 30, 2025, with 45.81% growth. This brings the company's revenue in the last twelve months to 23.39M, down -3.62% year-over-year. In the year 2024, Wuhan Healthgen Biotechnology had annual revenue of 25.22M with 3.92% growth. That makes Wuhan Healthgen Biotechnology the world's 41,016th largest company by revenue and 5,136th in China.
Revenue (ttm)
23.39M
Revenue Growth
-3.62%
P/S Ratio
609.01
Revenue / Employee
n/a
Employees
215
Market Cap
14.24B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.22M | 952.02K | 3.92% |
| Dec 31, 2023 | 24.26M | 10.86M | 81.08% |
| Dec 31, 2022 | 13.40M | -12.12M | -47.49% |
| Dec 31, 2021 | 25.52M | 3.95M | 18.33% |
| Dec 31, 2020 | 21.57M | 11.32M | 110.40% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.